{"id":49147,"date":"2022-10-04T18:02:03","date_gmt":"2022-10-04T16:02:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/"},"modified":"2022-10-04T18:02:03","modified_gmt":"2022-10-04T16:02:03","slug":"availability-of-poxels-2022-half-year-financial-report","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/","title":{"rendered":"Availability of Poxel&#8217;s 2022 Half-Year Financial Report"},"content":{"rendered":"<div>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52936341&amp;newsitemid=20221004005926&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=3388403ceaa6e8f2caa8913369eb747d\" rel=\"nofollow noopener\" shape=\"rect\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/4\/Logo_Without_Background.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg\"><\/a><\/p>\n<p>\nThe report includes:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nthe consolidated financial statements for the first half of 2022 closed on June 30, 2022;\n<\/li>\n<li>\nthe half-year activity report;\n<\/li>\n<li>\nthe Statutory Auditors&#8217; limited review report on the half-year information, which includes several observations;\n<\/li>\n<li>\nthe certificate of the person responsible for the half-year financial report.\n<\/li>\n<\/ul>\n<p>\nThe 2022 half-year financial report is available on the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.poxelpharma.com%2Fen_us%2Finvestors%2Fshareholder-information%2Fregulatory-documentation&amp;esheet=52936341&amp;newsitemid=20221004005926&amp;lan=en-US&amp;anchor=Company%27s+website&amp;index=2&amp;md5=88b0c917041d0e2ffd38245dc8d94152\" rel=\"nofollow noopener\" shape=\"rect\">Company&#8217;s website<\/a>.\n<\/p>\n<p>\n<b>Next financial press release: <\/b>2022 Third Quarter Financial Update, on November 8, 2022.\n<\/p>\n<p>\n<b>About Poxel SA<\/b>\n<\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical company<\/b> developing <b>innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including <b>non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. For the treatment of NASH, <b>PXL065<\/b> (deuterium-stabilized <i>R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.\n<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=52936341&amp;newsitemid=20221004005926&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=3&amp;md5=822e88fb72cce8046baebbcdbecaa305\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor relations \/ Media<\/b>\n<\/p>\n<p>\nAur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Senior Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;&#x3a;a&#117;&#x72;e&#108;&#x69;&#x65;&#46;&#98;&#x6f;z&#122;&#x61;&#x40;p&#111;&#x78;&#x65;&#108;&#x70;&#x68;a&#114;&#x6d;&#x61;&#46;&#99;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#97;&#x75;&#x72;e&#108;&#x69;e&#46;&#x62;o&#122;&#x7a;a&#64;&#x70;&#x6f;&#120;&#x65;&#x6c;p&#104;&#x61;r&#109;&#x61;&#46;&#99;&#x6f;&#x6d;<\/a><br \/>+33 6 99 81 08 36\n<\/p>\n<p>\nElizabeth Woo<br \/>\n<br \/>Senior Vice President, Investor Relations &amp; Communication<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;:&#x65;l&#x69;z&#97;&#x62;&#101;&#x74;&#104;&#x2e;&#119;&#x6f;o&#x40;p&#x6f;x&#101;&#x6c;&#112;&#x68;&#97;&#x72;&#109;&#x61;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">el&#105;&#122;&#97;&#x62;&#x65;&#x74;&#x68;&#x2e;wo&#111;&#64;&#112;&#x6f;&#x78;&#x65;&#x6c;&#x70;ha&#114;&#109;&#97;&#x2e;&#x63;&#x6f;&#x6d;<\/a>\n<\/p>\n<p>\nNewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#97;&#x69;l&#116;&#x6f;&#x3a;p&#111;&#x78;&#x65;l&#64;&#x6e;e&#119;&#x63;&#x61;p&#46;&#x65;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x6f;&#120;&#101;&#108;&#64;&#x6e;&#x65;&#x77;&#99;&#97;p&#46;&#x65;&#x75;<\/a><br \/>+33 1 44 71 94 94\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022. The report includes: the consolidated financial statements for the first half &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49147","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Availability of Poxel&#039;s 2022 Half-Year Financial Report - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Availability of Poxel&#039;s 2022 Half-Year Financial Report - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022. The report includes: the consolidated financial statements for the first half ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-04T16:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Availability of Poxel&#8217;s 2022 Half-Year Financial Report\",\"datePublished\":\"2022-10-04T16:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/\"},\"wordCount\":308,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005926\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/\",\"name\":\"Availability of Poxel's 2022 Half-Year Financial Report - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005926\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"datePublished\":\"2022-10-04T16:02:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005926\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221004005926\\\/en\\\/729413\\\/21\\\/Logo_Without_Background.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/availability-of-poxels-2022-half-year-financial-report\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Availability of Poxel&#8217;s 2022 Half-Year Financial Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Availability of Poxel's 2022 Half-Year Financial Report - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/","og_locale":"en_US","og_type":"article","og_title":"Availability of Poxel's 2022 Half-Year Financial Report - Pharma Trend","og_description":"LYON, France&#8211;(BUSINESS WIRE)&#8211;POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases, today announces the publication of its half-year financial report as of June 30, 2022. The report includes: the consolidated financial statements for the first half ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-04T16:02:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Availability of Poxel&#8217;s 2022 Half-Year Financial Report","datePublished":"2022-10-04T16:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/"},"wordCount":308,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/","url":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/","name":"Availability of Poxel's 2022 Half-Year Financial Report - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg","datePublished":"2022-10-04T16:02:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221004005926\/en\/729413\/21\/Logo_Without_Background.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/availability-of-poxels-2022-half-year-financial-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Availability of Poxel&#8217;s 2022 Half-Year Financial Report"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49147"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49147\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}